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Tumor growth is angiogenesis dependent. Angiogenic switch (the acquisition of an angiogenic pheno-
type) is essential for cervical carcinogenesis. Thrombospondin-1 (TSP-1) is an endogenous angiogenic
inhibitor with multiple functional domains and interacting receptors. The disruption of TSP-1 fence (the
expression in basal epithelia) occurred concordantly during the transition from low-grade squamous
intraepithelial lesion into high-grade squamous intraepithelial lesion. This concordance suggests that
TSP-1 plays a role in the regulation of angiogenic switch during cervical carcinogenesis. Tumor vascu-
lature as a therapeutic target offers a paradigm shift for anticancer therapy. Endothelial cells do not
appear to acquire resistance during antiangiogenic therapy. Low-and-frequent dose “metronic”
chemotherapy is found to be antiangiogenic, which is more effective in targeting tumor endothelia than
traditional large, single bolus doses. Meanwhile, the invasion process of cancers is associated with stroma
reaction, which is characterized by ﬁbroblasts' activation. In addition to the well-known angiogenesis
inhibitor, TSP-1 also has a novel role of blocking activated ﬁbroblasts (myoﬁbroblasts) from invading
cancer. Activated ﬁbroblasts during stroma reaction could be used as an efﬁcient drug delivery system to
prevent or slow the local growth of cancer cells. Elucidation of the mechanism by which ﬁbroblasts are
recruited into cancer stroma could lead to new insights into not only the mechanisms of cancer pro-
gression but also strategies for cancer treatment. A better understanding of stromal contributions to
cancer progression will likely result in the identiﬁcation of new therapeutics targeting the stroma.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Angiogenesis and stroma reaction are important during
carcinogenesis
Tumor growth is angiogenesis dependent
Angiogenesis is deﬁned as the formation of new blood vessels
by proliferation of new capillaries from preexisting microvessels.of interest.
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ses/by-nc-nd/4.0/).This process is distinct from vasculogenesis, which is deﬁned as
the formation of blood vessel de novo from angioblasts.1,2 Angio-
genesis involves degradation of the basement membrane sur-
rounding an existing capillary or venule, migration of endothelial
cells through the basement membrane to create a sprout, prolif-
eration of endothelial cells, formation of a lumen within the new
sprout and joining of two sprouts to from a functional capillary
loop, and vessel maturation.3,4 The idea that tumor growth is
angiogenesis dependent was ﬁrst proposed in 1971, allowing
antiangiogenic therapy to be used to treat cancer.5 The develop-
ment of a solid tumor progresses from a prevascular phase to a
vascular phase. The prevascular tumor does not induce angio-
genesis, is limited in size, and rarely metastasizes. The vascular-
ized tumor induces host microvessels to undergo angiogenesis.
The best characterized example is the hypoxia-dependentally Invasive Therapy. Published by Elsevier Taiwan LLC. This is an open access article under
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invade into the tumor stroma to form new blood vessels.6 Thus,
blocking angiogenesis can result in tumor dormancy, in which
tumors could not expand beyond a microscopic size.7 Within the
dormant tumors, the proliferating tumor cells are balanced by
apoptotic tumor cells and few, if any, microvessels.8Angiogenic switch during cervical carcinogenesis
Cervical cancer usually develops by a sequence of gradual,
stepwise events starting at low-grade squamous intraepithelial
lesion (LSIL) and progressing through high-grade SIL (HSIL), until
invasive cancer ensues.9 Tumor development and metastasis is a
complex process that includes transformation, proliferation, neo-
vascularization, and metastatic spread. The angiogenic switch-
acquisition of an angiogenic phenotype that is induced by a
change in the balance of angiogenesis activators and inhibitors, is
essential for tumor growth and metastasis.2,10 During carcino-
genesis, Toussaint-Smith et al11 and Bequet-Romero and Lopez-
Ocejo12 have described an increase in vascular endothelial growth
factor (VEGF) expression associated to the expression of human
papillomavirus type 16 oncoproteins E6 and E7. HPV oncoproteins
E6 and E7 disrupt the functions of the tumor suppressors p53. Loss
of p53 results in upregulation of VEGF and downregulation of
thrombospondin-1 (TSP-1). HPV 16 E6 and E7 oncoproteins may
contribute to the development of cervical cancer not only by
disrupting cell cycle regulation but also by creating a microenvi-
ronment that fosters the growth of tumors.11,12 It has been re-
ported that tumor microvasculature, accompanied by the
overexpression of VEGF, was progressively upregulated during the
process of cervical carcinogenesis.13 However, the timing of
angiogenic switch during cervical carcinogenesis remains contro-
versial.14 A debate exists regarding the ability of cervical intra-
epithelial neoplasia to induce angiogenesis.14e16 Smith-McCune
and Weidner14 found a signiﬁcant increase of microvessel den-
sity in the cervical intraepithelial neoplasia III lesions compared
with those underlying low-grade lesions.14 By contrast, reports
from Abulaﬁa et al16 show that microinvasive squamous cell car-
cinoma is angiogenic, but not carcinoma in situ. Wu et al17
examined different severities of cervical lesions in the same
slide, to eliminate the heterogeneity. The data showed that the
angiogenic switch in cervical carcinogenesis occurred during the
transition from LSIL to HSIL, and the neovascularization was
largely conﬁned to a narrow zone immediately underneath the
dysplastic epithelium. It further suggests that cervical carcino-
genesis is angiogenesis-dependent.Invasion process of cancer cells is associated with stroma reaction
Our understanding of cancer has largely come from the analysis
of aberrations within the tumor cell population. There is emerging
evidence to highlight the important role of tumor microenviron-
ment in tumorigenesis.18 Stroma reaction, also known as stroma-
genesis, is a host response of mesenchymal alteration induced in
cancer that produces a progressive and permissive mesenchymal
microenvironment, thereby supporting tumor progression.19
Paget20 ﬁrst proposed “seed and soil hypothesis” to highlight the
inﬂuence of tumor growth by interactions between malignant cells
and the tumor stroma in 1889. In the “seed and soil hypothesis” 20
of cancer biology, cancer cells are the “seeds,” and the microenvi-
ronment is the “soil” in which the “seeds” must ﬁnd a receptive
environment.21 The normal host microenvironment is nonpermis-
sive for neoplastic progression, and tumor-reactive stroma pro-
motes neoplastic growth and metastasis.22 Activation of the localinvasive environment seems to create a permissive ﬁeld for the
malignant cells.23
Stroma reaction is characterized by ﬁbroblast activation
Activated ﬁbroblasts, also called myoﬁbroblasts, are deﬁned by
the expression of a-smooth muscle actin, desmin, vimentin, etc. in
the ﬁbroblasts.24 Activated ﬁbroblasts can produce noncellular
scaffolds in response to extracellular stimuli, and create an envi-
ronment promoting tumor progression.25 In addition, activated ﬁ-
broblasts within the tumor stroma have a propensity to migrate
and invade like cancer cells.26 The proliferative activity of activated
ﬁbroblasts in cancer-induced stroma is closely linked to tumor
progression, lymph node, and distant organ metastasis of breast
cancer.27 Normal stromal cells may prevent epithelia from
becoming tumorigenic.28 Fibroblasts, as the major component of
stroma, are recruited and can convert into smooth muscle actin-
positive ﬁbroblasts, i.e., myoﬁbroblasts or activated ﬁbroblasts,
during stroma reaction.29,30 Myoﬁbroblasts appear at the invasion
front during stromal changes in cells.31
TSP-1 and cervical carcinogenesis
TSP-1 is a matricellular protein with diverse functions
Thrombospondins (TSPs) consist of a family of ﬁve extracellular
proteins that participate in cell-to-cell and cell-to-matrix commu-
nications.32 Among them, TSP-1 is a 450-kDa homotrimeric
matricellular glycoprotein with potent antiangiogenic effects. In
many tumor types, TSP-1 can block in vivo neovascularization and
decrease malignant tumor growth (e.g., skin, prostate, and bladder
cancers),33,34 whereas in others (e.g., breast cancer) it promotes
cancer cell adhesion, migration, and invasion.35 The differential
effects of TSP-1 on tumorigenesis indicate that TSP-1 exerts
different biological functions in different cell types. Also, TSP-1
interacts with multiple extracellular macromolecules and cell sur-
face receptors, thus exerting a wide range of responses.36,37 The
hypothesis of this review is “Can TSP-1 could inhibit cancer pro-
gression via targeting endothelial cells (EC) in angiogenesis and
ﬁbroblasts (F) in stroma reaction?” (Figure 1).
TSP-1 acts as “an angiogenic fence” during cervical carcinogenesis
Wu et al17 proposed a “TSP-1 fence” in which TSP-1 is mainly
localized on basal cervical epithelial cells, and arrayed like a barrier
in normal cervical epithelium or LSIL. TSP-1 decreases signiﬁcantly
during the transition from LSIL to HSIL, which is concomitant with
the increase of microvessel density counts. The temporal and
spatial concordance of TSP-1 downregulation and the emergence of
angiogenic imply that the “TSP-1 fence” may act as an angiogenic
barrier to inhibit angiogenesis that occurred in the early phase of
cervical carcinogenesis. The disappearance of the angiogenic bar-
rier may induce a vigorous angiogenic response for tumor growth
and perhaps tumor metastasis.38 TSP-1 does not appear to
contribute directly to the structural integrity of connective tissue
elements. Instead, TSP-1 acts by modulating the activity and
bioavailability of protease and growth factors and by interaction
with cell-surface receptors.39,40 Matrix metallopreoteases (MMPs)
have been shown to play an active role in the neovascularization of
tumors through their ability to degrade the extracellular ma-
trix.41,42 Bergers et al43 showed that the switch from vascular
quiescence to angiogenesis involves MMP-9, which is upregulated
in angiogenic islets and tumors. TSP-1 acts as a multifunctional
modulator of angiogenesis by modulating through the activity and
bioavailability of MMP-9.
Figure 1. The hypothesis of this review is “Can TSP-1 could inhibit cancer progression via targeting endothelial cells (EC) in angiogenesis and ﬁbroblasts (F) in stroma reaction?”.
F ¼ ﬁbroblast; MF ¼ myoﬁbroblast; M4 ¼ macrophages; TSP-1 ¼ thrombospondin-1.
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carcinogenesis?
The loss of the TSP-1 barrier in early cervical cancer lesions leads
to more aggressive and more vascular cancer phenotypes.17 In a
related situation, elevated angiogenesis inhibitor endostatin level
in conjunction with elevated VEGF are associated with either more
aggressive or with metastasis or shortened survival in renal cell
cancer, colon cancer, and soft tissue sarcoma.44e46 These observa-
tions showed that the angiogenic inhibitors can be modulated as a
result of changes in the tumor environment or in tumor disease
burden.47,48 Although circulating angiogenic activators such as
basic ﬁbroblast growth factor, VEGF, and angiogenin have been
evaluated not only as diagnostic and/or prognostic factors in cancer
patients, little is known about the clinical signiﬁcance of angiogenic
inhibitors. Neither the source nor the mechanism of TSP-1 protein
externalization has been clariﬁed in detail.49 The causeeeffect
relationship of TSP-1 as a gatekeeper during cervical carcinoma has
not been clearly established.50 The inverse relationship between
TSP-1 staining and severity of tumor lesions may be inﬂuenced
directly or indirectly by other processes (e.g., angiogenic factors).
The prevention of blood vessel development appears to be the
mechanism of action of many successful chemopreventive drugs of
natural or synthetic origin, termed “angioprevention,” which hy-
pothesizes that antiangiogenesis is at the basis of tumor preven-
tion, and also suggests that many antiangiogenic drugs could be
used for chemoprevention in higher-risk populations or in early
intervention.50 There is a growing body of experimental evidence
that antiangiogenic strategies will contribute to the future therapy
of cancer.51 Proof of such a relationship would provide a rationale
for the use of angiogenic inhibitors as preventive agents in patients
at high risk for developing cancer.TSP-1 inhibits stroma reaction by inhibiting activated ﬁbroblasts
from invading cancer
The downregulation of TSP-1 in cervical epithelium temporally
and spatially coincided with the emergence of angiogenic switchduring cervical carcinogenesis.17 However, the exact biologic roles
of TSP-1 in tumor stroma reaction and progression remain unde-
termined. Wu et al52 demonstrated a temporal inverse correlation
of TSP-1 and stromal marker expression during cervical carcino-
genesis using human clinical specimens. The inhibitory effect of
TSP-1 on stromal marker expression was further conﬁrmed in SCID
mouse xenografts using transfection of TSP-1 cDNA expression
vectors. Genetic manipulation of TSP-1 expression level in the cells
demonstrated that TSP-1-mediated inhibition of stroma reaction
was primarily due to the inhibition of activated ﬁbroblast migration
and invasion, rather than a direct effect on the stromal maker
expression. These results indicate that TSP-1 participates not only
in the negative regulation of angiogenesis but also stroma reaction
during cervical carcinogenesis.52 Therefore, TSP-1 has the potential
to inhibit tumor progression through blocking the migration and
invasion of activated ﬁbroblasts and leading to stroma
normalization.52
It has become increasingly clear that, from the context of
tumorestroma interactions, stroma plays an active role in tumor
progression.18 Stromal cells can acquire oncogenic transformation
following the exposure to carcinogen,53 manipulation of MMPs,54
and the recruitment of inﬂammatory cells to the stroma.55,56
Stroma reaction is often accompanied with stromal marker
expression and functional changes into an invasive phenotype.
Inhibition of stroma reaction by TSP-1 might be through reduced
expression of stromal markers and invasiveness or inhibition of
activated ﬁbroblast migration and recruitment to tumor stroma.Antiangiogenic therapy offers a paradigm shift for anticancer
therapy
Tumor vasculature as a therapeutic target
There exist several limitations in conventional chemo-
therapyde.g., it is easy for tumor cells to develop resistance to
cytotoxic agents that cause DNAdamage or disrupt DNA replication,
a phenomenon related to their genomic instability after varying
periods of sensitivity.57 The applied clinical strategy involves
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by administering combined cytotoxic agents at the maximum
tolerated dose. The goal is to obtain total eradication of the cancer
cells.58 However, most solid neoplasms are the result of multiple
genetic abnormalities and may contain heterogeneous sub-
populations of cells with different cell kinetics, and invasive and
metastatic properties.59 High levels of VEGF and low levels of TSP-1
were associated with a shorter survival. These results are in
agreement with those observed in a previous study that showed an
association between low levels of TSP-1 and high levels of VEGF
with a worse survival in nonsmall cell lung cancer. In particular,
levels of VEGF and TSP-1 correlated with prognosis and could be
useful as prognostic markers.60 There are some advantages to re-
gard tumor vasculature as the therapeutic targets. Tumor endo-
thelia, as compared with tumor cells, are composed of more
genetically stable cells. There is less likelihood of the emergence of
acquired chemoresistance. There are fewer systemic side effects
and less toxicity. They offer more feasibility of long-term admin-
istration and can be combined with other cytostatic and/or
molecularly targeted therapy.58 Systemic administration of in-
hibitors can easily reach the target at the concentration of drug
needed.58 The proliferation and migration of tumor endothelia can
be inhibited by naturally occurring angiogenesis inhibitors (e.g.,
endostatin, angiostatin, TSP-1).61,62 In addition, the number of
structurally abnormal vessels was reduced, suggesting that these
agents may “normalize” the tumor vasculature.63 Endothelial cells
do not appear to acquire resistance to some antiangiogenic agents.
It offers the possibility of reinducing a response after interruption
of therapy.
Low-dose “metronic” chemotherapy is antiangiogenic
Surprisingly, cytotoxic chemotherapy is found to have anti-
angiogenic effects, particularly when administered at low and
frequent doses. This scheduling is more effective in targeting tumor
endothelia than large single bolus doses followed by long rest pe-
riods.62 Conventional cytotoxic chemotherapeutic drugs were
designed to treat cancer by directly killing or inhibiting the pro-
liferation of rapidly dividing tumor cells. However, recent studies
have highlighted the possibility that cytotoxic agents might
reasonably be considered to have meaningful antiangiogenic ac-
tivity as a secondary mechanism.64 The use of chronically admin-
istered chemotherapeutic agents in frequent, even daily, schedule
with no prolonged drug-free breaks at low doses signiﬁcantly
below the maximum tolerated dose, is called “antiangiogenic” or
“metronomic” chemotherapy.65
The potential advantages of metronomic chemotherapeutic
include the following: (1) signiﬁcantly delay in the onset of
mutation-dependent mechanisms of acquired drug resistance,
because the target of the therapy is the genetically stable, activated
endothelial cells rather than the genetically unstable highly
mutable cancer cells66; (2) facilitation of the efﬁcacy and durability
of long-term integration of chemotherapy drugs with targeted
antiangiogenic agents67; (3) reduction or loss of traditional toxic
side effects due to the high sensitivity and selectivity charac-
ters68,69; and (4) induction of an antiangiogenic effect by
decreasing the mobilization and/or viability of circulating bone
marrow-derived endothelial precursor cells.70
TSP-1 plays angioinhibitory roles via a mediator of the low-dose
metronomic chemotherapy, in addition to direct endothelial tar-
geting. TSP-1 has been shown to possess potent angioinhibitory
effects in epithelial tumor development.34 In addition to the direct
targeting effects, Bocci et al66 reported that protracted exposure of
endothelial cells in vitro to low concentrations of cytotoxic
chemotherapeutic drugs in metronomic low-dosecyclophosphamide, caused marked induction of gene and protein
expression of TSP-1. The induction of TSP-1, as a secondary medi-
ator of the antiangiogenic effects, in low-dose metronomic
chemotherapy regimens can explain the “indirect” pathway-
induced growth arrest or apoptosis of endothelial cells.71 In sum-
mary, TSP-1 may exhibit its antiangiogenic effects in two ways:
direct targeting of the endothelium and by acting as a mediator of
metronomic chemotherapy.
A novel role for myoﬁbroblasts as a therapeutic target
Host stroma is an active participant during tumor progression,
whereas myoﬁbroblasts in the host stroma stimulate cancer inva-
sion. Maintenance of epithelial tissues needs the stroma. When the
epithelium changes, then the stroma inevitably follows. The
changes in the stroma drive invasion and metastasis, the hallmarks
of malignancy.31 However, Kinzler and Volgestein72 proposed
landscape defect to describe that changes in the epithelial
compartment might be secondary to alterations of the stroma re-
action that occur prior to epithelial changes. Therefore, the
epithelial compartment and stroma compartment might invade
each other. The interaction between the epithelial and mesen-
chymal compartments creates a local heterotypic “invasion ﬁeld”
from which the metastatic cell emerges and disseminates.73
Myoﬁbroblasts themselves are invasive, are present in the
stroma of many malignant tumors, and are frequently localized at
the front of invasion.31 Myoﬁbroblasts may participate at the
transition from the noninvasive toward the invasive phenotype is
compatiblewith their appearance in benign lesions that have a high
risk of progression toward invasive cancer. Myoﬁbroblasts invade
the tumor site, and this invasion may facilitate angiogenic invasion.
During avascular growth of developing hepatic metastases,
myoﬁbroblast-like cells are already present, prior to endothelial
cell recruitment.74
Therapeutic implication via inhibiting angiogenesis and
stroma reaction
Tumor angiogenesis can be used as a therapeutic target
Angiogenesis plays a critical role in the growth andmetastasis of
tumors. The antiangiogenesis effect of metronomic scheduling has
caused the paradigm shift from conventional dose-density
chemotherapy to metronomic scheduling. Signiﬁcant anti-
angiogenic and antitumor effects are unlikely to be achieved in the
clinical setting with a single chemotherapeutic agent at metro-
nomic doses. Pioneering studies by Kakeji and Teicher75 showed
the potentiality or synergism when angiogenic inhibitors were
combined with standard schedules of certain cytotoxic agents. The
efﬁcacy of metronomic chemotherapy can be signiﬁcantly
increased when administered in combination with antiangiogenic
drugs, such as antibodies against VEGF or VEGFR2.67 Browder
et al62 have used cyclophospamide and TNP-470 to reveal the
antiangiogenic capability of cancer chemotherapy to eradicate
chemoresistant tumors. VEGF promotes angiogenesis, a mediator of
disease progression in cervical cancer. Bevacizumab, a humanized
anti-VEGF monoclonal antibody, has single-agent activity in pre-
viously treated, recurrent disease. Most patients inwhom recurrent
cervical cancer develops have previously received cisplatin with
radiation therapy, which reduces the effectiveness of cisplatin at
the time of recurrence. The addition of bevacizumab to combina-
tion chemotherapy in patients with recurrent, persistent, or met-
astatic cervical cancer was associated with an improvement of 3.7
months in median overall survival.76 The proposed rationale for the
beneﬁcial effect of such combinations was based on their ability to
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neoplasia.77 Tumor endothelial targeting and tumor cell targeting
should not be thought of as mutually exclusive. Antiangiogenic
therapy can be added to chemotherapy, radiotherapy, immuno-
therapy, gene therapy, or any other traditionally cancer cell-
directed modality.78
As angiogenic inhibitors becomemorewidely used in anticancer
therapy, it will be important to reduce the harsh side effects and
risk of drug resistance of conventional chemotherapy.7 The para-
digm of anticancer treatment may shift from cancer-centered to
epigenic, endothelia-centered therapy.78 The ﬁnal goals of anti-
angiogenesis therapy are not to cure cancer; instead, it is to make
cancer more survivable and controllable, and eventually to be
converted to a chronic manageable disease, such as heart disease or
diabetes, especially in conjunction with radiation, chemotherapy,
and other treatments.79
Stroma reaction can be used as a therapeutic target
In viewing the fact that stromal therapy has recently emerged as
a strategy for cancer treatment, the clinical studies have shown the
effective treatment for many types of cancer.80 TSP-1 is potentially
an example of a molecule that is capable of altering the composi-
tion of the tumor stroma, in addition to inhibiting angiogenesis. By
inhibiting vascular cells, inhibiting recruitment, and preventing
ﬁbroblast activation, TSP-1 may play a role in “normalizing” the
tumor stroma and creating a microenvironment that is on-
permissive for tumor growth.52 Myoﬁbroblasts, the major compo-
nent of stroma, play a major role in tumor progression. However,
the deﬁnite role of TSP-1 in myoﬁbroblasts remains to be deter-
mined. Both the upregulation81 and repression82 of TSP-1 have
been reported to cause NIH3T3 in the malignant phenotype. It has
been reported that TSP-1, in cooperation with integrin, affects focal
adhesion kinase-dependent signaling to induce focal adhesion
disassembly and spreading.83,84 Further work on the biologic
mechanisms of myoﬁbroblast recruitment is needed, before myo-
ﬁbroblasts can be used as a therapeutic target or biologic tracer of
cancer cells.
Conclusion
After the clinical observation that TSP-1 plays an important role
in the regulation of angiogenic switch during cervical carcinogen-
esis, Wu et al17 further elucidated the causeeeffect relationship
between TSP-1 and tumorestroma interaction.52 TSP-1 reduces the
stroma reaction by changing the behaviors of myoﬁbroblasts.
Although further work on the biologic mechanisms of ﬁbroblast
recruitment is needed, the present study may offer the evidence
that TSP-1 can change the tumorestroma reaction during tumor
progression by acting on the activity of myoﬁbroblasts.52 It suggests
that ﬁbroblasts can be used as a biologic tracer of cancer cells and
could act as an efﬁcient drug delivery system to prevent or slow the
local growth of cancer cells. Elucidation of themechanism bywhich
ﬁbroblasts are recruited into cancer stroma could lead to new in-
sights into not only the mechanisms of cancer progression but also
strategies for cancer treatment. A better understanding of stromal
contributions to cancer progression will likely increase our
awareness of the importance of the combinatorial signals that
support and promote growth, dedifferentiation, invasion, and
ectopic survival and eventually result in the identiﬁcation of new
therapeutics targeting the stroma.31
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